OSIVAX - OSIVAX - CLINICAL PROOF OF CONCEPT OF OVX836, A SINGLE-SHOT BROADLY PROTECTIVE INFLUENZA A VACCINE FOR IMMEDIATE PROTECTION AGAINST EMERGING PANDEMIC STRAINS
Key Details
Description
OSIVAX - CLINICAL PROOF OF CONCEPT OF OVX836, A SINGLE-SHOT BROADLY PROTECTIVE INFLUENZA A VACCINE FOR IMMEDIATE PROTECTION AGAINST EMERGING PANDEMIC STRAINS
Context & Analysis
On Nov 13, 2025, Department of Health and Human Services obligated $19,485,392 to OSIVAX for osivax - clinical proof of concept of ovx836, a single-shot broadly protective influenza a vaccine for immediate protection against emerging pandemic strains. The award is classified under NAICS 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) and issued as a cost sharing contract. Competition extent: full and open competition with 1 offer received. The procurement used a NO SET ASIDE USED. set-aside. The contract is scheduled through Jul 24, 2028. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541714 — related awards are listed below.
Contractor Information
Similar Awards
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ALLUCENT GOVERNMENT SERVICES (US) LLC
$370.1M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ICON GOVERNMENT AND PUBLIC HEALTH SOLUTIONS, INC.
$330.2M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
TECHNICAL RESOURCES INTERNATIONAL, INC.
$317.1M
ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION
PARATEK PHARMACEUTICALS, INC
$265.3M
ASPR-18-04963 -- FUNDING FOR BALOXAVIR MARBOXIL ACTIVITIES FOR BASE PERIOD TASK UNDER THE GENENTECH OTA
GENENTECH INC
$243.7M
Stay Updated
Get notified about new opportunities matching your interests.